Administration of the nonselective CRH antagonist, α-helical CRH, decreases the exaggerated motility of the colon and visceral pain in IBS patients [12, 13], suggesting that CRH is an important regulator of stress-related brain-gut interactions in IBS. The gene discussed is CRH; the disease is irritable bowel syndrome.